Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Diphenyleneiodonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 16/20 | 1.00 |
| ▸ | CYBB | P04839 | 2/20 | 1.00 |
| ▸ | NOX5 | Q96PH1 | 2/20 | 1.00 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 1.00 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.93 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.93 |
| ▸ | NPC1 | O15118 | 2/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.93 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.93 |
| ▸ | TP53 | P04637 | 1/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.93 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.93 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.93 |
| ▸ | TSHR | P16473 | 1/20 | 0.93 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.93 |
| ▸ | THPO | P40225 | 1/20 | 0.93 |
| ▸ | STAT6 | P42226 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diphenyleneiodonium SCHEMBL30150802 | 1.00 | GPR3 (1.00) | GPR3CYBBNOX5NOX4NOX1 | |
| Diphenyleneiodonium SCHEMBL5547280 | 0.97 | GPR3 (0.94) | GPR3CYBBNOX5NOX4NOX1 | |
| Diphenyleneiodonium SCHEMBL29486373 | 0.97 | GPR3 (1.00) | GPR3CYBBNOX5NOX4NOX1 | |
| Diphenyleneiodonium SCHEMBL219548 | 0.97 | GPR3 (1.00) | GPR3CYBBNOX5NOX4NOX1 | |
| Diphenyleneiodonium SCHEMBL10834144 | 0.93 | GPR3 (0.93) | GPR3CYBBNOX5NOX4NOX1 | |
| Hydrochloric Acid SCHEMBL8168843 | 0.82 | — | — | |
| Diphenyleneiodonium SCHEMBL2057393 | 0.81 | GPR3 (0.73) | GPR3CYBBNOX5NOX4NOX1 | |
| SCHEMBL8367212 | 0.78 | — | — | |
| Diphenyleneiodonium SCHEMBL3733575 | 0.77 | GPR3 (0.68) | GPR3CYBBNOX5NOX4NOX1 | |
| SCHEMBL795440 | 0.70 | GPR3 (0.54) | GPR3CYBBNOX5NOX4NOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 643 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12553092-B2 | Energetic cancer stem cells (E-CSCS): a new hyper-metabolic and proliferative tumor cell phenotype, driven by mitochondrial energy | LUNELLA BIOTECH, INC. (CA) | 2026-02-17 | — | — | US | claimed |
| EP-3976197-B1 | THERAPEUTICS AND METHODS FOR PREDICTING AND OVERCOMING ENDOCRINE RESISTANCE IN BREAST CANCER | LUNELLA BIOTECH INC (CA) | 2025-07-16 | — | — | EP | claimed |
| WO-2025122600-A1 | COMPOSITIONS AND METHODS FOR TREATING ABERRANT NITROSYLATION | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-06-12 | — | — | WO | claimed |
| WO-2025038856-A1 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING AUTOIMMUNE DISEASE | NEW YORK UNIVERSITY (US) | 2025-02-20 | — | — | WO | claimed |
| EP-4172173-B1 | NEUTROPHIL-BINDING PEPTIDES | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2025-02-19 | — | — | EP | claimed |
| EP-3813949-B1 | ENERGETIC\" CANCER STEM CELLS (E-CSCS): A NEW HYPER-METABOLIC AND PROLIFERATIVE TUMOR CELL PHENOTYPE, DRIVEN BY MITOCHONDRIAL ENERGY | LUNELLA BIOTECH INC (CA) | 2024-05-29 | — | — | EP | claimed |
| US-11952431-B2 | Neutrophil-binding peptides | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-04-09 | — | — | US | claimed |
| CN-115645369-B | Lung-precisely-targeted liposome nanoparticle compound and preparation method and application thereof | 山东大学 | 2024-01-26 | — | — | CN | claimed |
| CN-116670174-A | Neutrophil binding peptides | 耶路撒冷希伯来大学伊萨姆研发有限公司 | 2023-08-29 | — | — | CN | claimed |
| US-20230203203-A1 | NEUTROPHIL-BINDING PEPTIDES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-06-29 | — | — | US | claimed |
| EP-0859591-B1 | USE OF AT LEAST ONE NO SYNTHASE INHIBITOR FOR TREATING SENSITIVE SKIN | OREAL (FR) | 2003-08-20 | — | — | EP | claimed |
| WO-2003026641-A2 | MODULATION OF STAT ACTIVITY | UNIVERSITY OF NOTTINGHAM (GB) | 2003-04-03 | — | — | WO | claimed |
| US-6471997-B1 | ANTAGONIST OF CALCITONIN GENE RELATED PEPTIDE, CGRP AND/OR OF SUBSTANCE P; COSMETIC | SOCIETE L'OREAL S.A. (FR) | 2002-10-29 | — | — | US | claimed |
| WO-2002069910-A2 | USE OF SUBSTANCES THAT PREVENT THAT THE NO SYNTHASE OF WARM-BLOODED ORGANISMS TAKES EFFECT, FOR PRODUCING COSMETIC OR DERMATOLOGICAL PREPARATIONS FOR THE TREATMENT AND/OR THE PROPHYLAXIS OF UNDESIRED SKIN PIGMENTATION | BEIERSDORF AG (DE) | 2002-09-12 | — | — | WO | claimed |
| US-20020037854-A1 | USE OF AT LEAST ONE NO SYNTHASE INHIBITOR FOR TREATING SENSITIVE SKIN | L'OREAL (FR) | 2002-03-28 | — | — | US | claimed |
| EP-1011656-A2 | A METHOD FOR TREATING TENSION-TYPE HEADACHE | Head Explorer ApS (DK) | 2000-06-28 | — | — | EP | claimed |
| EP-0765668-B1 | Extract of Iridaceas and compositions containing it | OREAL (FR) | 1999-03-17 | — | — | EP | claimed |
| US-5795574-A | COSMETICS WITH SUBSTANCE P ANTAGONIST | SOCIETE L'OREAL S.A. (FR) | 1998-08-18 | — | — | US | claimed |
| WO-1998019674-A2 | A METHOD FOR TREATING TENSION-TYPE HEADACHE | HEAD EXPLORER APS (DK) | 1998-05-14 | — | — | WO | claimed |
| EP-0761204-B1 | Use of extracts of filamentous, non photosynthetic bacteria and the composition containing them | OREAL (FR) | 1998-04-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12553092-B2 | Energetic cancer stem cells (E-CSCS): a new hyper-metabolic and proliferative tumor cell phenotype, driven by mitochondrial energy | TXNRD2, TXNRD1, TXN2 | GPR3 3700/4885CYBB 410/4885NOX5 480/4885 |
| US-20230203203-A1 | NEUTROPHIL-BINDING PEPTIDES | NCF1, LCP2, ELANE | GPR3 2503/4885CYBB 575/4885NOX5 1137/4885 |
| US-11952431-B2 | Neutrophil-binding peptides | NCF1, LCP2, ELANE | GPR3 2503/4885CYBB 575/4885NOX5 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.